Tesaglitazar, a dual PPAR-a/? agonist, hamster carcinogenicity, investigative animal and clinical studies.
AuthorsLindblom P, Berg AL, Zhang H, Westerberg R, Tugwood J, Lundgren H, Marcusson-Ståhl M, Sjögren N, Blomgren B, Öhman P, Skånberg I, Evans J, Hellmold H
JournalToxicol Pathol
PubMed ID22131108
'Tesaglitazar was developed as a dual peroxisome proliferator-activated receptor (PPARa/?). To support the clinical program, a hamster carcinogenicity study was performed. The only neoplastic findings possibly related to treatment with tesaglitazar were low incidences of hemangioma and hemangiosarcoma in the liver of male animals. A high-power, two-year investigative study with ... More
Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis.
AuthorsBoomsma RA, Geenen DL,
JournalPLoS One
PubMed ID22558198
We have previously shown that mesenchymal stem cells (MSC) improve function upon integration in ischemic myocardium. We examined whether specific cytokines and growth factors produced by MSCs are able to affect angiogenesis, cellular migration and apoptosis. Conditioned media (CM) was prepared by culturing MSC for 48 hours. CM displayed significantly ... More
Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells.
Abatacept modulates CD28-mediated T cell costimulation and is efficacious in the treatment of rheumatoid arthritis (RA). Its mechanism of action has not been fully elucidated but will likely reveal critical pathologic pathways in RA. We show that abatacept substantially modulated Ag-specific T and B cell responses in vivo. Ag-specific T ... More